date:Dec 18, 2013
nd brain structures associated with functions such as learning and memory, EFSA said in a statement from its Rome headquarters.
Some current guidance levels for acceptable exposure to acetamiprid and imidacloprid may not be protective enough to safeguard against developmental neurotoxicity and should be reduced.
A spokesman for the European Commission, which asked EFSA to carry out the assessment, said it would give Bayer and the makers of acetamiprid an opportunity to comment on the findings.